Delap Wealth Advisory LLC Takes Position in Natera, Inc. (NASDAQ:NTRA)

Delap Wealth Advisory LLC bought a new stake in shares of Natera, Inc. (NASDAQ:NTRA - Free Report) in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 4,190 shares of the medical research company's stock, valued at approximately $454,000.

A number of other large investors have also modified their holdings of NTRA. Itau Unibanco Holding S.A. acquired a new position in Natera during the second quarter worth about $28,000. Principal Securities Inc. bought a new stake in shares of Natera in the 4th quarter valued at approximately $32,000. GAMMA Investing LLC increased its position in Natera by 50.0% during the second quarter. GAMMA Investing LLC now owns 324 shares of the medical research company's stock worth $35,000 after buying an additional 108 shares during the last quarter. YHB Investment Advisors Inc. bought a new position in shares of Natera in the 1st quarter valued at approximately $36,000. Finally, Tobam acquired a new stake in shares of Natera in the second quarter worth $74,000. Institutional investors and hedge funds own 99.90% of the company's stock.

Natera Stock Performance

Shares of NTRA traded up $0.65 during trading hours on Friday, hitting $127.78. The company had a trading volume of 2,190,370 shares, compared to its average volume of 1,369,813. The business has a fifty day moving average of $114.45 and a 200-day moving average of $105.54. The company has a quick ratio of 4.01, a current ratio of 4.14 and a debt-to-equity ratio of 0.34. The firm has a market cap of $15.69 billion, a price-to-earnings ratio of -40.96 and a beta of 1.53. Natera, Inc. has a 12 month low of $36.90 and a 12 month high of $132.01.

Natera (NASDAQ:NTRA - Get Free Report) last issued its quarterly earnings data on Thursday, August 8th. The medical research company reported ($0.30) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.69) by $0.39. The company had revenue of $413.35 million during the quarter, compared to analysts' expectations of $343.00 million. Natera had a negative return on equity of 36.74% and a negative net margin of 21.47%. The business's revenue was up 58.1% on a year-over-year basis. During the same quarter in the previous year, the company posted ($0.97) earnings per share. Equities analysts anticipate that Natera, Inc. will post -1.96 EPS for the current fiscal year.

Insiders Place Their Bets

In other Natera news, CFO Michael Burkes Brophy sold 1,866 shares of the company's stock in a transaction on Wednesday, July 31st. The stock was sold at an average price of $99.65, for a total transaction of $185,946.90. Following the completion of the sale, the chief financial officer now directly owns 71,955 shares in the company, valued at $7,170,315.75. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other news, CFO Michael Burkes Brophy sold 1,866 shares of the company's stock in a transaction on Wednesday, July 31st. The shares were sold at an average price of $99.65, for a total transaction of $185,946.90. Following the completion of the transaction, the chief financial officer now directly owns 71,955 shares in the company, valued at $7,170,315.75. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Steven Leonard Chapman sold 37,500 shares of Natera stock in a transaction dated Monday, July 1st. The shares were sold at an average price of $108.10, for a total value of $4,053,750.00. Following the sale, the chief executive officer now directly owns 213,351 shares in the company, valued at $23,063,243.10. The disclosure for this sale can be found here. Insiders have sold a total of 93,921 shares of company stock worth $10,551,281 in the last quarter. Corporate insiders own 7.60% of the company's stock.

Analyst Upgrades and Downgrades

A number of analysts have issued reports on NTRA shares. Robert W. Baird raised their target price on Natera from $117.00 to $120.00 and gave the company an "outperform" rating in a report on Friday, August 9th. Morgan Stanley increased their target price on shares of Natera from $125.00 to $132.00 and gave the stock an "overweight" rating in a research report on Tuesday, August 13th. UBS Group lowered their target price on Natera from $160.00 to $145.00 and set a "buy" rating for the company in a research note on Friday, August 9th. Jefferies Financial Group initiated coverage on Natera in a research report on Monday, June 3rd. They issued a "buy" rating and a $142.00 price objective for the company. Finally, TD Cowen upped their price objective on Natera from $137.00 to $145.00 and gave the company a "buy" rating in a report on Friday, August 9th. One investment analyst has rated the stock with a sell rating and fifteen have given a buy rating to the company's stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average target price of $120.07.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.